Search clinical trials for: Acute Myeloblastic Leukaemia (AML)

Total 25338 results

Assiut University

Recruiting

Explore the Relationship Between Platelet Count and Bleeding Score in ITP

ITP - Immune Thrombocytopenia

Egypt
Celltrion

Active, not recruiting

Study to Evaluate and Compare the Efficacy and Safety of AZM and AML Combined and Alone in Mild-to-moderate Essential Hypertensive Subjects

Essential Hypertension

Korea, Republic of
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC

Completed

Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS)

United States
Technische Universität Dresden
German Federal Ministry of Education and Research; Groupe Francophone des Myelodysplasies and other collaborators

Active, not recruiting

Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia (TUD-APOLLO-064)

Acute Promyelocytic Leukemia

France, Germany, Italy, Netherlands, Spain
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute; Celgene

Recruiting

DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission

Acute Myelogenous Leukemia

United States
King's College London
King's College Hospital NHS Trust

Unknown

B7.1/IL-2 Leukaemia Cell Vaccine for Non-Transplant AML RFUSIN2-AML2 (NTX)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute
Jazz Pharmaceuticals

Completed

A Post-Marketing Observational Study of VYXEOS™

Therapy-Related Acute Myeloid Leukemia | Acute Myeloid Leukemia With Myelodysplasia-Related Changes

United States
Merck Sharp & Dohme LLC

Terminated

A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005)

DLBCL | AML Including AML de Novo and AML Secondary to MDS
Beat AML, LLC

Recruiting

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

Previously Untreated Acute Myeloid Leukemia

United States
Ruijin Hospital

Recruiting

Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS (PANDA-T0)

P53 Mutation | Myeloid Malignancy | MDS | Aml

China
Capital Research Institute of Pediatrics

Unknown

Improved Post-Transplant Cyclophosphamide Regimens for Pediatric Patients With Refractory AML

Hematopoietic System--Cancer

China
German AML Cooperative Group

Unknown

Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic

Relapsed Acute Promyelocytic Leukemia | Refractory Acute Promyelocytic Leukemia

Germany
Zhujiang Hospital
Nanfang Hospital of Southern Medical University; The Third Affiliated Hospital... and other collaborators

Terminated

CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia (AML)

Relapsed/Refractory Acute Myeloid Leukemia(AML)

China
Shenzhen People's Hospital

Unknown

Medium Dose of Cytarabine and Mitoxantrone (HAM)

Chemotherapy | Acute Myelogenous Leukemia

China
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Yanda Ludaopei Hospital

Unknown

Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia

Acute Myelocytic Leukemia

China
The First Affiliated Hospital of Soochow University
The First Affiliated Hospital with Nanjing Medical University; The Affiliated... and other collaborators

Recruiting

Anti-FLT3 CAR T-cell Therapy in FLT3 Positive Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Hospices Civils de Lyon

Recruiting

Pharmacokinetics Variability of Posaconazole (PCZ) and Its Glucuronide Metabolite During Induction and Consolidation Treatments in Patients With Acute Myeloid Leukemia (AML): a Covariate Analysis With the Tablets Formulation and Evaluation of the Potential Risk of Hepatotoxicity (Posa-Pk)

Leukemia, Myeloid, Acute

France
Astellas Pharma Global Development, Inc.

Completed

Treatment Patterns and Key Healthcare Resource Use in Acute Myeloid Leukemia (AML) With or Without FMS-like Tyrosine Kinase-3 (FLT3) Mutation Study Based on Retrospective Chart Review

Acute Myeloid Leukemia (AML)

United States
PETHEMA Foundation

Completed

VILMA: Therapeutic Results in Acute Mieloblastic Leukemia in Patients Older Than 60 Years

AML

Spain
Ruijin Hospital

Not yet recruiting

Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR

AML, Adult

China
Abramson Cancer Center at Penn Medicine
Bristol-Myers Squibb

Recruiting

Assessment of Geriatric Evaluations Impact on New AML Guidance (AGE-ING)

AML, Adult

United States
University Hospital Inselspital, Berne

Terminated

HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt. (HDMM)

AML, Adult

Switzerland
Ludwig-Maximilians - University of Munich

Completed

DC Vaccination for Postremission Therapy in AML

Acute Myeloid Leukemia

Germany
Grupo Argentino de Tratamiento de la Leucemia Aguda

Recruiting

RWE of 1st Line Treatment in Adults With AML From 18 to 70 Years Old.

Acute Myeloid Leukemia, Adult

Argentina
Sohag University

Unknown

Effectivness of Topical Tacrolimus Monotherapy in Patients With Vitiligo

Vitiligo | Tacrolimus

Egypt
H Scott Boswell
Takeda

Terminated

Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib

AML | AML, Adult

United States
Institut de Recherches Internationales Servier

Completed

Efficacy and Safety of Perindopril 5 mg / Indapamide 1.25 mg / Amlodipine 5 mg Fixed Combination in Hypertension

Hypertension

China
David Iberri

Terminated

Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML) With Multilineage Dysplasia Following Myelodysplastic Syndrome, in Adults | AML (Adult) With 11q23 (MLL) Abnormalities | AML (Adult) With Del (5q) | AML (Adult) With Inv (16) (p13; q22) | AML (Adult) With t (16;16) (p13; q22) | AML (Adult) With t (8; 21) (q22; q22) and other conditions

United States
University Hospital, Bordeaux

Not yet recruiting

ObServatory Children Acute RElated Therapy Leukemia (OSCARE)

Leukemia, Myeloid, Acute
Zhejiang University
Hangzhou Qihangene Biotech Co.,Ltd.

Recruiting

Natural Killer(NK) Cell Therapy Targeting CLL1 in Acute Myeloid Leukemia

AML, Adult

China
Therapeutic Advances in Childhood Leukemia Consortium
Bristol-Myers Squibb

Active, not recruiting

Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML

AML, Childhood

United States
Rubius Therapeutics

Terminated

RTX-240 Monotherapy and in Combination With Pembrolizumab

Solid Tumor, AML Adult

United States
The First Affiliated Hospital of Soochow University

Recruiting

CD38-targeted Chimeric Antigen Receptor T Cell (CART) in Relapesd or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
The First Affiliated Hospital of Soochow University
Second Affiliated Hospital of Soochow University; The Second People's Hospital... and other collaborators

Unknown

Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60

Acute Myeloid Leukemia | Induction Chemotherapy

China
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute; National Institutes of Health (NIH); Medivation... and other collaborators

Active, not recruiting

Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission

AML | Acute Myelogenous Leukemia

United States
Ciceri Fabio
Associazione Italiana per la Ricerca sul Cancro; Gruppo Italiano Trapianto...

Recruiting

Analysis of the Immunobiology of Acute Myeloid Leukemia Relapses After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for the Generation of Guidelines and Personalized Therapeutic Pathways (GITMO-RELAPSE)

Acute Myeloid Leukemia, in Relapse

Italy
Essen Biotech

Not yet recruiting

Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML (BAH244)

Acute Myeloid Leukemia | AML | AML, Adult | AML, Adult Recurrent

China
Assiut University
South Egypt Cancer Institute

Completed

Comparison of Diagnostic Yield Among M-FISH, FISH Probe Panel and Conventional Cytogenetic Analysis in AML

Acute Myeloid Leukemia

Egypt
University Health Network, Toronto

Completed

A Study of Imatinib With Reinduction Chemotherapy Using Mitoxantrone, Etoposide and Cytarabine in Patients With Relapsed/Refractory C-kit Positive (AML) Acute Myeloid Leukemia

Leukemia

Canada
Assiut University

Not yet recruiting

Evaluation of Clinical and Pathological Characteristics and Routine Treatment of Patients With Prostate Cancer

Prostate Cancer
GWT-TUD GmbH

Completed

Assessment of Body, Liver and Labile Plasma Iron and Their Association With Outcome and Immunological Recovery in Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Stem Cell Transplantation - ALLIVE (ALLogeneic Iron inVEstigators) Observational Trial (ALLIVE)

MDS and AML Prior to Allogeneic SCT

Germany
Carbiogene Therapeutics Co. Ltd.
Zhejiang Provincial People's Hospital

Recruiting

Clinical Study of Anti-ILT3 CAR-T Therapy for R/R AML(M4/M5)

AML M5 | AML M4

China
Centre Hospitalier Universitaire de Nice

Recruiting

Oral Azacitidine Maintenance Post-CPX 351 (ORAZ-351)

Acute Myeloid Leukemia

France
Princess Maxima Center for Pediatric Oncology
Daiichi Sankyo

Recruiting

CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients (CHIP-AML22/Q)

Acute Myeloid Leukemia in Children

Netherlands
ASLAN Pharmaceuticals

Completed

A Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States, Australia, Singapore
Fox Chase Cancer Center
Novartis Pharmaceuticals

Terminated

Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus (SAGE)

Sporadic Angiomyolipomas (AMLs)

United States
Eilean Therapeutics

Recruiting

Study of Single and Multiple Ascending Doses of ZE46-0134 in Healthy Volunteers

AML

Australia
National Research Center for Hematology, Russia
Federal Research Clinical Center of Federal Medical & Biological Agency,... and other collaborators

Recruiting

The Role of Allo-HSCT in MRD-negative Patients With AML Under the Age of 60 Years in the First Complete Remission

AML

Russian Federation
Glycostem Therapeutics BV

Recruiting

Registry of Patients Having Received oNKord®

AML

Switzerland, Germany
Etan Orgel
Astellas Pharma Global Development, Inc.

No longer available

Individual Patient Expanded Access Gilteritinib (ASP2215)

AML

United States

Search clinical trials for: Acute Myeloblastic Leukaemia (AML)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Trinidad & Tobago

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations